Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Health

Exciting Developments in Pharmaceuticals and Biotechnology: RSV Therapy and Vaccine Rollout

Exciting developments are on the horizon in the world of pharmaceuticals and biotechnology as positive data emerges for RSV therapy and vaccine rollout. The past year has seen significant progress in RSV research, with the approval of multiple vaccines and a new treatment for infants targeting RSV disease.

In a cover story for this month, we delve into the implications of these vaccines and treatments reaching those in need, starting with the initial rollout in Spain and the potential lessons it holds for global distribution.

One of the highlights of this issue is an exclusive interview with the director of Biomedical Advanced Research and Development Authority (BARDA)’s medical countermeasures programs. The interview sheds light on BARDA’s future focus areas and strategies.

Delving deeper into the realm of pharmaceuticals, don’t miss out on insights into the pricing implications of the world’s most expensive therapy, the rising trend of molecular glues, and more.

Stay updated with the latest news and analysis from the pharmaceutical and biotech industry in the latest issue of Pharma Technology Focus. Explore in-depth coverage and expert analysis to stay informed about the ever-evolving landscape of healthcare innovation.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *